Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

Find insight on lithium, lumber, the impact of tariffs and more in the latest Market Talks covering Basic Materials.

Morgan Stanley reaffirmed Tesla as its top pick, maintaining a $430 price target despite mixed analyst ratings. Some firms, ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

While many of its peers abandon the lithium sector, Green Technology Metals is priming itself for development.

We recently compiled a list of the Wall Street Optimism Spills Over to These 10 Stocks on Friday. In this article, we are ...

Bank of Montreal (TSE:BMO – Free Report) (NYSE:BMO) had its price target increased by Canaccord Genuity Group from C$154.00 ...

Shares of DoubleVerify touched a record low after its full-year outlook missed Wall Street estimates, its fourth-quarter revenue came in lower than expected and two firms cut their target prices.

The general mood among these heavyweight investors is divided, with 13% leaning bullish and 72% bearish. Among these notable ...

The general mood among these heavyweight investors is divided, with 22% leaning bullish and 55% bearish. Among these notable ...